Pharmacological and surgical treatments for obesity

American Heart Journal

Volumn 151, Issue 3, 2006, Pages 604-624

  DeWald, Tracy ^a   Khaodhiar, Lalita ^b   Donahue, Mark P ^a   Blackburn, George ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; AMFEPRAMONE; AMPHETAMINE; AMYLASE INHIBITOR; ANTIOBESITY AGENT; BENZPHETAMINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; DEXAMPHETAMINE; DEXFENFLURAMINE; DITAL; DOSPAN; EPHEDRINE; FENFLURAMINE; FLUOXETINE; LY 355101; MAZANAR; MAZINDOL; METFORMIN; METHAMPHETAMINE; MIGLITOL; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; PHENDIMETRAZINE TARTRATE; PHENTERMINE; PHENTERMINE RESIN; PHENYLPROPANOLAMINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SIBUTRAMINE; SUCROSE POLYESTER; TERBUTALINE; TETRAHYDROLIPSTATIN; UNINDEXED DRUG;

ABDOMINAL PAIN; ANGINA PECTORIS; ANOREXIA; BARIATRIC SURGERY; BILIOPANCREATIC BYPASS; BLOATING; BRAIN HEMORRHAGE; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; CONSTIPATION; DIABETIC OBESITY; DIAPHORESIS; DIARRHEA; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DRUG INDUCED HEADACHE; EDEMA; ENERGY EXPENDITURE; FECES INCONTINENCE; FLATULENCE; FOOD INTAKE; GASTRIC BANDING; GASTROINTESTINAL TOXICITY; GASTROPLASTY; HEART ARRHYTHMIA; HEART PALPITATION; HEART VALVE REGURGITATION; HUMAN; HYPERREFLEXIA; HYPERTENSION; INSOMNIA; JEJUNOILEAL BYPASS; LIFESTYLE; MEDICAL RESEARCH; MENTAL INSTABILITY; MORBIDITY; MYOCLONUS; NAUSEA AND VOMITING; NERVOUSNESS; NURSING; OBESITY; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RESTLESSNESS; RISK REDUCTION; ROUX Y ANASTOMOSIS; SEIZURE; SEIZURE SUSCEPTIBILITY; SEROTONIN SYNDROME; SHIVERING; SIDE EFFECT; STOMACH BYPASS; STROKE; TACHYCARDIA; THORAX PAIN; TREMOR; UNITED STATES; UNSPECIFIED SIDE EFFECT; URINARY URGENCY; VALVULAR HEART DISEASE; VASCULAR DISEASE; VASODILATATION; XEROSTOMIA;

ANTI-OBESITY AGENTS; ANTICHOLESTEREMIC AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; APPETITE DEPRESSANTS; BARIATRIC SURGERY; CAFFEINE; DIETARY SUPPLEMENTS; ENZYME INHIBITORS; EPHEDRINE; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE; OBESITY; PEPTIDE HORMONES; SEROTONIN AGENTS;

EID: 33344475650     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2005.03.007     Document Type: Conference Paper

References (187)

1. G.A. Bray Health hazards associated with overweight G.A. Bray Contemporary diagnosis and management of obesity 1998 Handbooks in Health Care Newtown (Pa) 68 103
2. United States Department of Health and Human Services, National Institutes of Health, and National Heart, Lung, and Blood Institute Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report 1998 National Institutes of Health Bethesda (Md) [NIH Publication No. 98-4083]
3. F.X. Pi-Sunyer Medical hazards of obesity Ann Intern Med 119 1993 655 660
4. M.E. Lean, T.S. Han, and J.C. Seidell Impairment of health and quality of life using new US federal guidelines for the identification of obesity Arch Intern Med 159 1999 837 843
5. L.V. Sjostrom Morbidity of severely obese patients Am J Clin Nutr 55 1992 508S 515S
6. C.H. Halsted, J. Newton, and S.D. Phinney Obesity and its health risks Curr Opin Gastroenterol 12 1996 204 209
7. A.M. Wolf, and G.A. Colditz Current estimates of the economic cost of obesity in the United States Obes Res 6 1998 97 106
8. P.G. Kopelman Obesity as a medical problem Nature 404 2000 635 643
9. L.F. Van Gaal Dietary treatment of obesity G.A. Bray C. Bouchard W.P.T. James Handbook of obesity 1998 Marcel Dekker New York 875 890
10. D. McTavish, and R.C. Heel Dexfenfluramine: a review of its pharmacological properties and therapeutic potential in obesity Drugs 43 1992 713 733
11. M. Weintraub Long-term weight control: the National Heart, Lung, and Blood Institute Funded Multimodal Intervention Study Clin Pharmacol Ther 51 1992 581 585
12. M. Weintraub, P.R. Sundaresan, and M. Madan Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo Clin Pharmacol Ther 51 1992 586 594
13. M. Weintraub, P.R. Sundaresan, and B. Schuster Long-term weight control study. II (weeks 34 to 104). An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise Clin Pharmacol Ther 51 1992 595 601
14. M. Weintraub, P.R. Sundaresan, and B. Schuster Long-term weight control study. III (weeks 104 to 156). An open-label study of dose adjustment of fenfluramine and phentermine Clin Pharmacol Ther 51 1992 602 607
15. M. Weintraub, P.R. Sundaresan, and B. Schuster Long-term weight control study. IV (weeks 156 to 190). The second double-blind phase Clin Pharacol Ther 51 1992 608 614
16. M. Weintraub, P.R. Sundaresan, and B. Schuster Long-term weight control study. V (weeks 190 to 210). Follow-up of participants after cessation of medication Clin Pharmacol Ther 51 1992 615 618
17. M. Weintraub, P.R. Sundaresan, and C. Cox Long-term weight control study. VI. Individual participant response patterns Clin Pharmacol Ther 51 1992 619 633
18. M. Weintraub Long-term weight control study: conclusions Clin Pharmacol Ther 51 1992 642 646
19. R.J. Kuczmarski, K.M. Flegal, and S.M. Campbell Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991 JAMA 272 1994 205 211
20. K.M. Flegal, M.D. Carroll, and R.J. Kuczmarski Overweight and obesity in the United States: prevalence and trends, 1960-1994 Int J Obes Relat Metab Disord 22 1998 39 47
21. World Health Organization Obesity: preventing and managing the global epidemic. Report of a WHO Consultation 1998 WHO Geneva (Switzerland) [WHO Technical Report Series, No. 894]
22. L.K. Khan, M.K. Serdula, and B.A. Bowman Use of prescription weight loss pills among U.S. adults in 1996-1998 Ann Intern Med 134 2001 282 286
23. J.E. Manson, W.C. Willett, and M.J. Stampfer Body weight and mortality among women N Engl J Med 333 1995 677 685
24. I.M. Lee, J.E. Manson, and C.H. Hennekens Body weight and mortality. A 27-year follow-up of middle-aged men JAMA 270 1993 2823 2828
25. J. Stevens, J. Cai, and E.R. Pamuk The effect of age on the association between body-mass index and mortality N Engl J Med 338 1998 1 7
26. R.L. Atkinson, and V.S. Hubbard Report on the NIH workshop on pharmacologic treatment of obesity Am J Clin Nutr 60 1994 153 156
27. National Task Force on the Prevention and Treatment of Obesity Long-term pharmacotherapy in the management of obesity JAMA 276 1996 1907 1915
28. E.C. Mun, G.L. Blackburn, and J.B. Matthews Current status of medical and surgical therapy for obesity Gastroenterology 120 2001 669 681
29. G.A. Bray, and F.L. Greenway Current and potential drugs for treatment of obesity Endocr Rev 20 1999 805 875
30. J. Cerulli, B.M. Lomaestro, and M. Malone Update on the pharmacotherapy of obesity Ann Pharmacother 32 1998 88 102
31. G.A. Bray A concise review on the therapeutics of obesity Nutrition 16 2000 953 960
32. J. Kolanowski A risk-benefit assessment of anti-obesity drugs Drug Saf 20 1999 119 131
33. W.N. Kernan, C.M. Viscoli, and L.M. Brass Phenylpropanolamine and the risk of hemorrhagic stroke N Engl J Med 343 2000 1826 1832
34. Physicians' desk reference 54th ed. 2000 Medical Economics Montvale (NJ)
35. Drug information handbook 6th ed. 1998-1999 Lexi-Comp Hudson (Ohio)
36. Orlistat for obesity Med Lett Drugs Ther 41 1999 55 56
37. S. Inoue Clinical studies with mazindol Obes Res 3 1995 549S 552S
38. D.J. King, and N. Devaney Clinical pharmacology of sibutramine hydrochloride (BTS 54524), a new antidepressant, in healthy volunteers Br J Clin Pharmacol 26 1988 607 611
39. L. Abenhaim, Y. Moride, and F. Brenot Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group N Engl J Med 335 1996 609 616
40. L. Lansberg, and J.B. Young Physiology and pharmacology of the autonomic nervous system E. Braunwald A.S. Fauci D.L. Kasper Harrison's principles of internal medicine 15th ed. 2001 McGraw-Hill New York 438 445
41. S. Tsujii, and G.A. Bray Food intake of lean and obese Zucker rats following ventricular infusions of adrenergic agonists Brain Res 587 1992 226 232
42. G.A. Bray Evaluation of drugs for treating obesity Obes Res 3 1995 425S 434S
43. C. Gundlah, K.F. Martin, and D.J. Heal In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor J Pharmacol Exp Ther 283 1997 581 591
44. W. McNeely, and K.L. Goa Sibutramine. A review of its contribution to the management of obesity Drugs 56 1998 1093 1124
45. C.A. Luque, and J.A. Rey Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity Ann Pharmacother 33 1999 968 978
46. W.R. Buckett, P.C. Thomas, and G.P. Luscombe The pharmacology of sibutramine hydrochloride (BTS 54 524), a new antidepressant which induces rapid noradrenergic down-regulation Prog Neuropsychopharmacol Biol Psychiatry 12 1988 575 584
47. L.F. Van Gaal, M.A. Wauters, and I.H. De Leeuw Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contribution to obesity treatment Exp Clin Endocrinol Diabetes 106 1998 35 40
48. D.H. Ryan, P. Kaiser, and G.A. Bray Sibutramine: a novel new agent for obesity treatment Obes Res 3 1995 553S 559S
49. I.P. Connoley, Y.L. Liu, and I. Frost Thermogenic effects of sibutramine and its metabolites Br J Pharmacol 126 1999 1487 1495
50. D.L. Hansen, S. Toubro, and M.J. Stock The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction Int J Obes Relat Metab Disord 23 1999 1016 1024
51. G.A. Bray, D.H. Ryan, and D. Gordon A double-blind randomized placebo-controlled trial of sibutramine Obes Res 4 1996 263 270
52. M. Weintraub, A. Rubio, and A. Golik Sibutramine in weight control: a dose-ranging, efficacy study Clin Pharmacol Ther 50 1991 330 337
53. S.P. Jones, I.G. Smith, and F. Kelly Long-term weight loss with sibutramine [abstract] Int J Obes Relat Metab Disord 19 1995 41
54. M.E. Lean Sibutramine-a review of clinical efficacy Int J Obes Relat Metab Disord 21 1997 S30 S36
55. M. Apfelbaum, P. Vague, and O. Ziegler Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine Am J Med 106 1999 179 184
56. W.P. James, A. Astrup, and N. Finer Effect of sibutramine on weight maintenance after weight loss: a randomized trial. STORM Study Group. Sibutramine trial of obesity reduction and maintenance Lancet 356 2000 2119 2125
57. H. Sternbach The serotonin syndrome Am J Psychiatry 148 1991 705 713
58. B.K. Smith, D.A. York, and G.A. Bray Activation of hypothalamic serotonin receptors reduced intake of dietary fat and protein but not carbohydrate Am J Physiol 277 1999 R802 R811
59. C.T. Dourish Multiple serotonin receptors: opportunities for new treatments for obesity? Obes Res 3 1995 449S 462S
60. H.M. Connolly, J.L. Crary, and M.D. McGoon Valvular heart disease associated with fenfluramine-phentermine N Engl J Med 337 1997 581 588
61. J.G. Jollis, C.K. Landolfo, and J. Kisslo Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities Circulation 101 2000 2071 2077
62. S. Garattini, T. Mennini, and C. Bendotti Neurochemical mechanism of action of drugs which modify feeding via the serotoninergic system Appetite 7 1986 15 38
63. S. Belohlavkova, J. Simak, and A. Kokesova Fenfluramine-induced pulmonary vasoconstriction: role of serotonin receptors and potassium channels J Appl Physiol 91 2001 755 761
64. N.J. Weissman Appetite suppressants and valvular heart disease Am J Med Sci 321 2001 285 291
65. B. Guy-Grand, M. Apfelbaum, and G. Crepaldi International trial of long-term dexfenfluramine in obesity Lancet 2 1989 1142 1145
66. A. Carvajal, J. Garcia del Pozo, and I. Martin de Diego Efficacy of fenfluramine and dexfenfluramine in the treatment of obesity: a meta-analysis Methods Find Exp Clin Pharmacol 22 2000 285 290
67. R. Bross, and L.J. Hoffer Fluoxetine increases resting energy expenditure and basal body temperature in humans Am J Clin Nutr 61 1995 1020 1025
68. Wellbutrin [package insert] 2000 Glaxo Wellcome Research Triangle Park (NC)
69. H. Croft, E. Settle Jr, and T. Houser A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline Clin Ther 21 1999 643 658
70. N. Harto-Truax, W.C. Stern, and L.L. Miller Effects of bupropion on body weight J Clin Psychiatry 44 1983 183 186
71. R.H. Weisler, J.A. Johnston, and C.G. Lineberry Comparison of bupropion and trazodone for the treatment of major depression J Clin Psychopharmacol 14 1994 170 179
72. K.M. Gadde, C.B. Parker, and L.G. Maner Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women Obes Res 9 2001 544 551
73. E.C. Settle, S.M. Stahl, and S.R. Batey Safety profile of sustained-release bupropion in depression: results of three clinical trials Clin Ther 21 1999 454 463
74. A.J. Scheen, and P.J. Lefebvre Pharmacological treatment of obesity: present status Int J Obes Relat Metab Disord 23 1999 47 53
75. A. Golay, and E. Bobbioni The role of dietary fat in obesity Int J Obes Relat Metab Disord 21 1997 S2 S11
76. G.A. Bray, and B.M. Popkin Dietary fat intake does affect obesity! Am J Clin Nutr 68 1998 1157 1173
77. J.B. Hauptman, F.S. Jeunet, and D. Hartmann Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipostatin) Am J Clin Nutr 55 1992 309S 313S
78. M.L. Drent, and E.A. van der Veen Lipase inhibition: a novel concept in the treatment of obesity Int J Obes Relat Metab Disord 17 1993 241 244
79. R. Guerciolini Mode of action of orlistat Int J Obes Relat Metab Disord 21 1997 S12 S23
80. K.M. Hvizdos, and A. Markham Orlistat: a review of its use in the management of obesity Drugs 58 1999 743 760
81. M.L. Drent, I. Larsson, and T. William-Olsson Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study Int J Obes Relat Metab Disord 19 1995 221 226
82. W.P. James, A. Avenell, and J. Broom A one-year trial to assess the value of orlistat in the management of obesity Int J Obes Relat Metab Disord 21 1997 S24 S30
83. L. Sjostrom, A. Rissanen, and T. Andersen Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group Lancet 352 1998 167 172
84. L.F. Van Gaal, J.I. Broom, and G. Enzi Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group Eur J Clin Pharmacol 54 1998 125 132
85. S. Rossner, L. Sjostrom, and R. Noack Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years of treatment with orlistat for obesity. European Orlistat Obesity Study Group Obes Res 8 2000 49 61
86. K.H. Lucas, and B. Kaplan-Machlis Orlistat-a novel weight loss therapy Ann Pharmacother 35 2001 314 328
87. A.T. Melia, S.G. Koss-Twardy, and J. Zhi The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers J Clin Pharmacol 36 1996 647 653
88. J. Zhi, A.T. Melia, and S.G. Koss-Twardy The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of beta-carotene in healthy volunteers J Clin Pharmacol 36 1996 152 159
89. M.H. Davidson, J. Hauptman, and M. DiGirolamo Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial JAMA 281 1999 235 242
90. S. Tonstad, D. Pometta, and D.W. Erkelens The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia Eur J Clin Pharmacol 46 1994 405 410
91. Z. Pataky, and A. Golay Effect of treatment with orlistat for one year on blood pressure in obese patients [abstract] Int J Obes Relat Metab Disord 23 1999 S175
92. P.A. Hollander, S.C. Elbein, and I.B. Hirsch Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study Diabetes Care 21 1998 1288 1294
93. D.M. Prince, and M.A. Welschenbach Olestra: a new food additive J Am Diet Assoc 98 1998 565 569
94. A.B. Thomson, R.H. Hunt, and N.L. Zorich Review article: olestra and its gastrointestinal safety Aliment Pharmacol Ther 12 1998 1185 1200
95. K.D. Lawson, S.J. Middleton, and C.D. Hassall Olestra, a nonabsorbed, noncaloric replacement for dietary fat: a review Drug Metab Rev 29 1997 651 703
96. R.E. Patterson, A.R. Kristal, and J.C. Peters Changes in diet, weight, and serum lipid levels associated with olestra consumption Arch Intern Med 160 2000 2600 2604
97. M.D. Thornquist, A.R. Kristal, and R.E. Patterson Olestra consumption does not predict serum concentrations of carotenoids or fat-soluble vitamins in free-living humans: early results from the sentinel site of the Olestra Post-Marketing Surveillance Study J Nutr 130 2000 1711 1718
98. S.G. Wannamethee, and A.G. Shaper Weight change and duration of overweight and obesity in the incidence of type 2 diabetes Diabetes Care 22 1999 1266 1272
99. J.E. Everhart, D.J. Pettitt, and P.H. Bennett Duration of obesity increases the incidence of NIDDM Diabetes 41 1992 235 240
100. A. Klip, and L.A. Leiter Cellular mechanism of action of metformin Diabetes Care 13 1990 696 704
101. M. Stumvoll, N. Nurjhan, and G. Perriello Metabolic effects of metformin in non-insulin-dependent diabetes mellitus N Engl J Med 333 1995 550 554
102. B.F. Clark, and L.J. Duncan Comparison of chlorpropamide and metformin treatment on weight and blood-glucose response of uncontrolled obese diabetics Lancet 1 1968 123 126
103. E. Haupt, B. Knick, and T. Koschinky Oral antidiabetic combination therapy with sulphonylureas and metformin Diabete Metab 17 1991 224 231
104. L.S. Hermann, P.O. Bitzen, and T. Kjellstrom Comparative efficacy of metformin and glibenclamide in patients with non-insulin-dependent diabetes mellitus Diabetes Metab 17 1991 201 208
105. J.F. Munro, A.C. MacCuish, and A. Marshall Weight-reducing effect of diguanides in obese non-diabetic women BMJ 2 1969 13 15
106. L. Papoz, D. Job, and E. Eschwege Effect of oral hypoglycaemic drugs on glucose tolerance and insulin secretion in borderline diabetic patients Diabetologia 15 1978 373 380
107. A. Lee, and J.E. Morley Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes Obes Res 6 1998 47 53
108. G. Paolisso, L. Amato, and R. Eccellente Effect of metformin on food intake in obese subjects Eur J Clin Invest 28 1998 441 446
109. United Kingdom Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 352 1998 854 865
110. A. Astrup, S. Toubro, and N.J. Christensen Pharmacology of thermogenic drugs Am J Clin Nutr 55 1992 246S 248S
111. E. Jequier, R. Munger, and J. Felber Thermogenic effects of various beta-adrenoceptor agonists in humans: their potential usefulness in the treatment of obesity Am J Clin Nutr 55 1992 249S 251S
112. O.L. Tulp, and C.L. Buck Caffeine and ephedrine stimulated thermogenesis in LA-corpulent rats Comp Biochem Physiol C 85 1986 17 19
113. A. Astrup Thermogenic drugs as a strategy for the treatment of obesity Endocrine 13 2000 207 212
114. Y.L. Liu, S. Toubro, and A. Astrup Contribution of beta 3-adrenoceptor activation to ephedrine-induced thermogenesis in humans Int J Obes Relat Metab Disord 19 1995 678 685
115. A.G. Dulloo, and D.S. Miller The thermogenic properties of ephedrine/methylxanthine mixtures: human studies Int J Obes 10 1986 467 481
116. A. Astrup, L. Breum, and S. Toubro The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy-restricted diet. A double-blind trial Int J Obes Relat Metab Disord 16 1992 269 277
117. I. Wiener, A.G. Tilkian, and M. Palazzolo Coronary artery spasm and myocardial infarction in a patient with normal coronary arteries: temporal relationship to pseudoephedrine ingestion Cathet Cardiovasc Diagn 20 1990 51 53
118. L.B. To, J.F. Sangster, and D. Rampling Ephedrine-induced cardiomyopathy Med J Aust 2 1980 35 36
119. C.A. Haller, and N.L. Benowitz Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids N Engl J Med 343 2000 1833 1838
120. C.N. Boozer, J.A. Nasser, and S.B. Heymsfield An herbal supplement containing Ma Huang-guarana for weight loss: a randomized, double-blind trial Int J Obes Relat Metab Disord 25 2001 316 324
121. G. Egger, D. Cameron-Smith, and R. Stanton The effectiveness of popular, non-prescription weight loss supplements Med J Aust 171 1999 604 608
122. I.L. Mertens, and L.F. Van Gaal Promising new approaches to the management of obesity Drugs 60 2000 1 9
123. P. Collins, and G. Williams Drug treatment of obesity: from past failures to future successes? Br J Clin Pharmacol 51 2001 13 25
124. M. Kojima, H. Hosoda, and Y. Date Ghrelin is a growth-hormone-releasing acylated peptide from stomach Nature 402 1999 656 660
125. Y. Date, M. Kojima, and H. Hosada Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans Endocrinology 141 2000 4255 4261
126. M.W. Schwartz, S.C. Woods, and D. Porte Jr Central nervous system control of food intake Nature 404 2000 661 671
127. D.E. Cummings, J.Q. Purnell, and R.S. Frayo A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans Diabetes 50 2001 1714 1719
128. H. Ariyasu, K. Takaya, and T. Tagami Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans J Clin Endocrinol Metab 86 2001 4753 4758
129. M. Tschop, C. Weyer, and P.A. Tataranni Circulating ghrelin levels are decreased in human obesity Diabetes 50 2001 707 709
130. D.E. Cummings, D.S. Weigle, and R.S. Frayo Ghrelin levels after diet-induced weight loss or gastric bypass surgery N Engl J Med 346 2002 1623 1630
131. S.M. Poykko, E. Kellokoski, and S. Horkko Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes Diabetes 52 2003 2546 2553
132. J.Q. Purnell, D.S. Weigle, and P. Breen Ghrelin levels correlate with insulin levels, insulin resistance, and high-density lipoprotein cholesterol, but not with gender, menopausal status, or cortisol levels in humans J Clin Endocrinol Metab 88 2003 5747 5752
133. F. Tassone, F. Broglio, and S. Destanfanis Neuroendocrine and metabolic effects of acute ghrelin administration in human obesity J Clin Endocrinol Metab 88 2003 5478 5483
134. A.M. Wren, L.J. Seal, and M.A. Cohen Ghrelin enhances appetite and increases food intake in humans J Clin Endocrinol Metab 86 2001 5992 5995
135. American College of Cardiology Scientific Sessions 2004, New Orleans, LA.
136. L.V. Sjostrom Mortality of severely obese subjects Am J Clin Nutr 55 1992 516S 523S
137. E.F. Foley, P.N. Benotti, and B.C. Borlase Impact of gastric restrictive surgery on hypertension in the morbidly obese Am J Surg 163 1992 294 297
138. J.L. Carson, M.E. Ruddy, and A.E. Duff The effect of gastric bypass surgery on hypertension in morbidly obese patients Arch Intern Med 154 1994 193 200
139. S.A. Olsson, B.G. Petersson, and R. Sorbris Effects of weight reduction after gastroplasty on glucose and lipid metabolism Am J Clin Nutr 40 1984 1273 1280
140. C.A. Herbst, T.A. Hughes, and J.T. Gwynne Gastric bariatric operation in insulin-treated adults Surgery 95 1984 209 214
141. W.J. Pories, M.S. Swanson, and K.G. MacDonald Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus Ann Surg 222 1995 339 350
142. H.J. Sugerman, P.L. Baron, and R.P. Fairman Hemodynamic dysfunction in obesity hypoventilation syndrome and the effects of treatment with surgically induced weight loss Ann Surg 207 1988 604 613
143. H.J. Sugerman, R.P. Fairman, and R.K. Sood Long-term effects of gastric surgery for treating respiratory insufficiency of obesity Am J Clin Nutr 55 1992 597S 601S
144. C.H. Kim, and M.G. Sarr Severe reflux esophagitis after vertical banded gastroplasty for treatment of morbid obesity Mayo Clin Proc 67 1992 33 35
145. H.J. Sugerman, J.M. Kellum Jr, and E.J. DeMaria Conversion of failed or complicated vertical banded gastroplasty to gastric bypass in morbid obesity Am J Surg 171 1996 263 269
146. J.F. Amaral, W. Tsiaris, and T. Morgan Reversal of benign intracranial hypertension by surgically induced weight loss Arch Surg 122 1987 946 949
147. J.M. Kellum, E.J. DeMaria, and H.J. Sugerman The surgical treatment of morbid obesity Curr Probl Surg 35 1998 791 858
148. C.D. Sjostrom, M. Peltonen, and H. Wedel Differentiated long-term effects of intentional weight loss on diabetes and hypertension Hypertension 36 2000 20 25
149. National Institutes of Health Conference Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel Ann Intern Med 115 1991 956 961
150. J.H. Payne, and L.T. DeWind Surgical treatment of obesity Am J Surg 118 1969 141 147
151. J.D. Halverson, L. Wise, and M.F. Wazna Jejunoileal bypass for morbid obesity. A critical appraisal Am J Med 64 1978 461 475
152. J.M. Kroyer, and W.M. Talbert Jr Morphologic liver changes in intestinal bypass patients Am J Surg 139 1980 855 859
153. H. Sugerman Gastric surgery for morbid obesity M.J. Zinner Maingot's abdominal operations 1997 Appleton & Lange Stamford (Conn) 1057 1077
154. N. Scopinaro, E. Gianetta, and G.F. Adami Biliopancreatic diversion for obesity at eighteen years Surgery 119 1996 261 268
155. M.M. Murr, B.M. Balsiger, and F.P. Kennedy Malabsorptive procedures for severe obesity: comparison of pancreaticobiliary bypass and very very long limb Roux-en-Y gastric bypass J Gastrointest Surg 3 1999 607 612
156. M. Lagace, P. Marceau, and S. Marceau Biliopancreatic diversion with a new type of gastrectomy: some previous conclusions revisited Obes Surg 5 1995 411 418
157. S. Marceau, S. Biron, and M. Lagace Biliopancreatic diversion, with distal gastrectomy 250 cm and 50 cm limbs: long-term results Obes Surg 5 1995 302 307
158. P. Marceau, F.S. Hould, and S. Simard Biliopancreatic diversion with duodenal switch World J Surg 22 1998 947 954
159. C.A. Gomez Gastroplasty in morbid obesity Surg Clin North Am 59 1979 1113 1120
160. W.G. Pace, E.W. Martin Jr, and T. Tetirick Gastric partitioning for morbid obesity Ann Surg 190 1979 392 400
161. E.E. Mason Vertical banded gastroplasty for obesity Arch Surg 117 1982 701 706
162. L.D. MacLean, B.M. Rhode, and J. Sampalis Results of the surgical treatment of obesity Am J Surg 165 1993 155 160
163. M.L. Nightengale, M.G. Sarr, and K.A. Kelly Prospective evaluation of vertical banded gastroplasty as the primary operation for morbid obesity Mayo Clin Proc 66 1991 773 782
164. L. Howard, M. Malone, and A. Michalek Gastric bypass and vertical banded gastroplasty-a prospective randomized comparison and 5-year follow-up Obes Surg 5 1995 55 60
165. H.J. Sugerman, J.V. Starkey, and R. Birkenhauer A randomized prospective trial of gastric bypass versus vertical banded gastroplasty for morbid obesity and their effects on sweets versus non-sweets eaters Ann Surg 205 1987 613 624
166. K.B. Jones Jr Experience with the Roux-en-Y gastric bypass, and commentary on current trends Obes Surg 10 2000 183 185
167. O. Bo, and O. Modalsli Gastric banding, a surgical method of treating morbid obesity: preliminary report Int J Obes 7 1983 493 499
168. L. Kuzmak Stoma adjustable silicone gastric banding Probl Gen Surg 9 1992 298 317
169. M. Belachew, M. Legrand, and V. Vincent Laparoscopic placement of adjustable silicone gastric band in the treatment of morbid obesity: how to do it Obes Surg 5 1995 66 70
170. P.E. O'Brien, W.A. Brown, and A. Smith Prospective study of a laparoscopically placed, adjustable gastric band in the treatment of morbid obesity Br J Surg 86 1999 113 118
171. M. Belachew, M. Legrand, and V. Vincent Laparoscopic adjustable gastric banding World J Surg 22 1998 955 963
172. S.B. Doldi, G. Micheletto, and E. Lattuada Adjustable gastric banding: 5-year experience Obes Surg 10 2000 171 173
173. P. Forsell, and G. Hellers The Swedish Adjustable Gastric Banding (SAGB) for morbid obesity: 9-year experience and a 4-year follow-up of patients operated with a new adjustable band Obes Surg 7 1997 345 351
174. A. Westling, K. Bjurling, and M. Ohrvall Silicone-adjustable gastric banding: disappointing results Obes Surg 8 1998 467 474
175. E.E. Mason, and C. Ito Gastric bypass Ann Surg 170 1969 329 339
176. C. Ito, E.E. Mason, and L.D. Besten Experimental studies on gastric bypass versus standard ulcer operations Tohoku J Exp Med 97 1969 269 277
177. W.O. Griffen Jr, V.L. Young, and C.C. Stevenson A prospective comparison of gastric and jejunoileal bypass procedures for morbid obesity Ann Surg 186 1977 500 509
178. J.F. Alden Gastric and jejunoileal bypass. A comparison in the treatment of morbid obesity Arch Surg 112 1977 799 806
179. R.E. Brolin, H.A. Kenler, and J.H. Gorman Long-limb gastric bypass in the superobese. A prospective randomized study Ann Surg 215 1992 387 395
180. S. Meryn, D. Stein, and E.W. Straus Pancreatic polypeptide, pancreatic glucagons and enteroglucagon in morbid obesity and following gastric bypass operation Int J Obes 10 1986 37 42
181. J.M. Kellum, J.F. Kuemmerle, and T.M. O'Dorisio Gastrointestinal hormone responses to meals before and after gastric bypass and vertical banded gastroplasty Ann Surg 211 1990 763 770
182. H.J. Sugerman, G.L. Londrey, and J.M. Kellum Weight loss with vertical banded gastroplasty and Roux-Y gastric bypass for morbid obesity with selective versus random assignment Am J Surg 157 1989 93 102
183. A.C. Wittgrove, G.W. Clark, and L.J. Tremblay Laparoscopic gastric bypass, Roux-en-Y: preliminary report of five cases Obes Surg 4 1994 353 357
184. T. Naitoh, M. Gagner, and A. Garcia-Ruiz Hand-assisted laparoscopic digestive surgery provides safety and tactile sensation for malignancy or obesity Surg Endosc 13 1999 157 160
185. P.R. Schauer, S. Ikramuddin, and W.F. Gourash Laparoscopic Roux-en-Y gastric bypass: a case report at one-year follow-up J Laparoendosc Adv Surg Tech A 9 1999 101 106
186. R.A. de la Torre, and J.S. Scott Laparoscopic Roux-en-Y gastric bypass: a totally intra-abdominal approach-technique and preliminary report Obes Surg 9 1999 492 498
187. A.C. Wittgrove, and G.W. Clark Laparoscopic gastric bypass, Roux-en-Y-500 patients: technique and results, with 3-60 month follow-up Obes Surg 10 2000 233 239